Sulindac Slows Growth of Colon Polyps, May Prevent Colon Cancer

OncologyONCOLOGY Vol 10 No 2
Volume 10
Issue 2

Sulindac sulfone, a nonsteroidal anti-inflammatory drug (NSAID) recently tested in the laboratories of the Arizona Cancer Center, may prove to be an effective colon cancer preventive agent.

Sulindac sulfone, a nonsteroidal anti-inflammatory drug (NSAID)recently tested in the laboratories of the Arizona Cancer Center,may prove to be an effective colon cancer preventive agent.

Within the last few years, reports the Arizona center, researchhas suggested that NSAIDs may be effective in preventing colorectalcancer. Sulindac reduces the growth of colon polyps in patientswith familial adenomatous polyposis (FAP). Since most colon cancersdevelop from colon polyps, stopping polyp growth may reduce cancerrisk.

"Although sulindac prevents polyp growth, many patients experienceside effects, such as upper gastrointestinal (GI) disturbances.Consequently, only about one third of patients can tolerate thedrug for prolonged treatment periods," explains David S.Alberts, MD, director of cancer prevention and control. Dr. Albertsworked on the NSAID research with Klaus Brendel, PhD, professorof pharmacology, and Lee Hixson, MD, who since has moved fromthe University of Arizona.

"Most patients cannot stay on sulindac long enough for itto be an effective chemopreventive agent because this would requiredaily use, perhaps for life," Dr. Alberts said.

"In looking for a better colon cancer preventive drug, wedecided to study derivatives of sulindac, to find the active ingredientresponsible for reducing colon polyps. The object was to finda better way to deliver the active ingredient and reduce the sideeffects."

Several research papers suggested that sulindac's side effectswere related to the production of prostaglandins. Sulindac inhibitsproduction of prostaglandins, and many researchers believe thatstopping prostaglandin production prevents tumor formation, accordingto Dr. Alberts.

However, more recent studies conflict with this viewpoint andshow that tumors grow even in the absence of prostaglandin. Dr.Alberts' group decided to focus their research on sulindac sulfone,an "inactive" metabolite of sulindac. Previously sulindacsulfone was not shown to be active as an anti-inflammatory agent,and it does not inhibit prostaglandin production.

"Preclinical indications suggest that sulindac sulfone maybe as effective as sulindac in reducing colon polyp growth inpatients with familial adenomatous polyposis but without the GIside effects. This means patients who can't take sulindac mayhave a chance to reduce their risk of colon cancer by taking sulindacsulfone," says Dr. Alberts.

The sulindac sulfone study was supported by a grant from CellPathways, Inc., of Denver, Colorado, which has licensed the drugfrom the Technology Transfer Office of the University of Arizona.Cell Pathways also coordinated the clinical trials. The phaseI trial, which involved 33 people without FAP, didn't identifyany safety problems with the drug, but "we still have a longway to go in the testing process," says Floyd Nicholls, chiefexecutive officer of Cell Pathways. The next study, which willstart later this year, will involve patients with FAP.

Related Videos
Rates of obesity appear to correlate with increasing incidence of cancer in young populations, according to Monique Gary, DO, MSc, FACS.
Data from a ctDNA analysis of the phase 3 INTRIGUE study indicate that KIT mutational status may be associated with response to certain Tyrosine kinase inhibitors in GIST, according to an expert from the Yale Cancer Center in New Haven, Massachusetts.
Future research into the management of unresectable hepatocellular carcinoma may involve combining local therapies with checkpoint inhibitors like durvalumab and tremelimumab, according to Ghassan K. Abou-Alda, MD.
Patients with unresectable hepatocellular carcinoma who have recurrent disease following surgery or locally advanced diseases who will likely progress on local therapy may have an opportunity to benefit from tremelimumab and durvalumab following its FDA approval, according to Ghassan K. Abou-Alfa, MD.
Ghassan K. Abou-Alfa, MD, discusses the importance of improving access to novel therapies and combinations for patients with hepatocellular carcinoma across the world.
Ghassan K. Abou-Alfa, MD, spoke about the recent approval of tremelimumab plus durvalumab for patients with unresectable hepatocellular carcinoma, based on results from the phase 3 HIMALAYA trial.
Howard A. Burris, MD, highlighted previous findings of the phase 3 TOPAZ-1 trial assessing durvalumab plus gemcitabine and cisplatin vs placebo plus gemcitabine and cisplatin in advanced biliary tract cancer and patient-reported outcomes (PRO)data that were presented at 2022 ASCO.
Shubham Pant, MD discusses key findings from a basket trial examining the use of erdafitinib in patients with gastrointestinal cancers.
Related Content